Clinical Trial Update: Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration [Phase 3]

View source ↗

Summary

Phase 3 trial comparing safety and thyroid remnant ablation after 131I in post-thyroidectomy euthyroid patients treated with Thyrogen versus hypothyroid patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Neoplasms

Drugs mentioned

• Thyrogen (thyrotropin alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Thyroid Neoplasms | Phase 3 | Status: COMPLETED